Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genfit SA
Cash & Cash Equivalents
Genfit SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Cash & Cash Equivalents
€101.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
5%
|
|
|
Valneva SE
PAR:VLA
|
Cash & Cash Equivalents
€109.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
Inventiva SA
PAR:IVA
|
Cash & Cash Equivalents
€99.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Cash & Cash Equivalents
$61.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-16%
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash & Cash Equivalents
$194.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Abivax SA
PAR:ABVX
|
Cash & Cash Equivalents
€516.7m
|
CAGR 3-Years
168%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
101.1m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Cash & Cash Equivalents amounts to 101.1m EUR.
What is Genfit SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%
Over the last year, the Cash & Cash Equivalents growth was 24%. The average annual Cash & Cash Equivalents growth rates for Genfit SA have been -9% over the past three years , -10% over the past five years , and 5% over the past ten years .
